Biotech Values

[genisi]

Sorry for not being clear, by "low-quality" I referred to characterization quality in terms of the sameness to the branded drug. The topic of my posts indeed is not a new branded drug—it’s an application to the FDA for a generic version of Lovenox and my points there were that I'm pretty sure Teva had characterized the generic drug using all the available techniques and I don't believe they would have submitted an ANDA without doing so or in case the drug had been found to be so different from the branded.